PSTV
Price:
$1.18
Market Cap:
$6.96M
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Au...[Read more]
Industry
Biotechnology
IPO Date
2001-07-11
Stock Exchange
NASDAQ
Ticker
PSTV
According to Plus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.13M. This represents a change of 7.14% compared to the average of 8.53M of the last 4 quarters.
The mean historical Enterprise Value of Plus Therapeutics, Inc. over the last ten years is 15.10M. The current 9.13M Enterprise Value has changed 5.95% with respect to the historical average. Over the past ten years (40 quarters), PSTV's Enterprise Value was at its highest in in the March 2015 quarter at 153.86M. The Enterprise Value was at its lowest in in the September 2019 quarter at -2230216.10.
Average
15.10M
Median
9.53M
Minimum
-4073320.00
Maximum
61.88M
Discovering the peaks and valleys of Plus Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.21%
Maximum Annual Enterprise Value = 61.88M
Minimum Annual Increase = -419.44%
Minimum Annual Enterprise Value = -4073320.00
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.12M | -127.58% |
2022 | -4073320.00 | -416.59% |
2021 | 1.29M | -83.06% |
2020 | 7.59M | -419.44% |
2019 | -2377388.00 | -120.74% |
2018 | 11.46M | -16.88% |
2017 | 13.79M | -55.78% |
2016 | 31.18M | 7.21% |
2015 | 29.08M | -53.00% |
2014 | 61.88M | -69.52% |
The current Enterprise Value of Plus Therapeutics, Inc. (PSTV) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-554355.83
5-year avg
710.75K
10-year avg
15.10M
Plus Therapeutics, Inc.’s Enterprise Value is less than Aditxt, Inc. (14.61M), greater than Palisade Bio, Inc. (-4438971.00), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Quoin Pharmaceuticals, Ltd. (-162664.00), greater than Zura Bio Limited (-9969663.00), greater than Altamira Therapeutics Ltd. (909.70K), less than Immix Biopharma, Inc. (30.53M), greater than Enveric Biosciences, Inc. (202.96K), less than First Wave BioPharma, Inc. (9.55M), greater than Dermata Therapeutics, Inc. (-3823196.00), greater than Panbela Therapeutics, Inc. (4.75M), greater than ContraFect Corporation (-2860000.00), greater than Protara Therapeutics, Inc. (2.28M), greater than Vaccinex, Inc. (6.56M), less than Monopar Therapeutics Inc. (100.06M), less than Miromatrix Medical Inc. (90.06M), greater than Surrozen, Inc. (250.67K), greater than Avenue Therapeutics, Inc. (1.25M), greater than Hoth Therapeutics, Inc. (-2189764.00), greater than NeuroBo Pharmaceuticals, Inc. (-1095056.00), greater than Virax Biolabs Group Limited (5.36M),
Company | Enterprise Value | Market cap |
---|---|---|
14.61M | $4.82M | |
-4438971.00 | $3.24M | |
-3300245.00 | $3.24M | |
-162664.00 | $2.95M | |
-9969663.00 | $178.25M | |
909.70K | $1.60M | |
30.53M | $49.14M | |
202.96K | $3.31M | |
9.55M | $5.99M | |
-3823196.00 | $2.32M | |
4.75M | $1.69M | |
-2860000.00 | $0 | |
2.28M | $49.31M | |
6.56M | $9.41M | |
100.06M | $106.08M | |
90.06M | $92.95M | |
250.67K | $29.74M | |
1.25M | $3.84M | |
-2189764.00 | $5.80M | |
-1095056.00 | $20.42M | |
5.36M | $8.73M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Plus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Plus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Plus Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Plus Therapeutics, Inc. (PSTV)?
What is the 3-year average Enterprise Value for Plus Therapeutics, Inc. (PSTV)?
What is the 5-year average Enterprise Value for Plus Therapeutics, Inc. (PSTV)?
How does the current Enterprise Value for Plus Therapeutics, Inc. (PSTV) compare to its historical average?